These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 35785927)
21. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. Tausend W; Downing C; Tyring S J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703 [TBL] [Abstract][Full Text] [Related]
22. Durability and long-term outcomes of biologic therapies in psoriasis. Rusiñol L; Carmona-Rocha E; Puig L Expert Rev Clin Immunol; 2024; 20(1):71-82. PubMed ID: 37610817 [TBL] [Abstract][Full Text] [Related]
23. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. Armstrong AW; Read C JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307 [TBL] [Abstract][Full Text] [Related]
24. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737 [TBL] [Abstract][Full Text] [Related]
25. Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond. Pușcaș AD; Morar II; Vesa ȘC; Cătană A; Pușcaș C; Ilieș RF; Orasan RI Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239484 [TBL] [Abstract][Full Text] [Related]
26. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551 [TBL] [Abstract][Full Text] [Related]
27. Emerging therapies in psoriasis: a systematic review. Lee EB; Amin M; Bhutani T; Wu JJ Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027 [TBL] [Abstract][Full Text] [Related]
28. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review. Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926 [TBL] [Abstract][Full Text] [Related]
29. Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. Leonardi CL; See K; Burge R; Sun Z; Zhang Y; Mallbris L; Garrelts A; Warren RB Adv Ther; 2022 May; 39(5):2256-2269. PubMed ID: 35316500 [TBL] [Abstract][Full Text] [Related]
30. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Bonifati C; Morrone A; Cristaudo A; Graceffa D Dermatol Ther; 2021 Jan; 34(1):e14584. PubMed ID: 33236471 [TBL] [Abstract][Full Text] [Related]
32. Individual Article: Brodalumab Is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update. Issa NT; Kircik L J Drugs Dermatol; 2023 Oct; 22(10):SF378632s5-SF378632s15. PubMed ID: 37801535 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of emerging immunotherapies in psoriasis. Yiu ZZ; Warren RB Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988 [TBL] [Abstract][Full Text] [Related]
35. Japanese guidance for use of biologics for psoriasis (the 2019 version). Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M; J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326 [TBL] [Abstract][Full Text] [Related]
36. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593 [TBL] [Abstract][Full Text] [Related]
37. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Yang K; Oak ASW; Elewski BE Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128 [TBL] [Abstract][Full Text] [Related]
38. Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors. Takeshima R; Kamata M; Suzuki S; Ito M; Watanabe A; Uchida H; Chijiwa C; Okada Y; Azuma S; Nagata M; Egawa S; Hiura A; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Tada Y J Dermatol; 2024 Sep; 51(9):1216-1224. PubMed ID: 38804254 [TBL] [Abstract][Full Text] [Related]
39. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Hu Y; Chen Z; Gong Y; Shi Y Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053 [TBL] [Abstract][Full Text] [Related]
40. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]